#CCTG trial spotlight for #LeukemiaAwarenessMonth & #ChildhoodCancerAwarenessMonth: The ALC6 study is testing if adding another drug to standard treatment improves outcomes for young adults with newly diagnosed B-cell acute lymphoblastic leukemia.
#myeloMATCH
Trial Info -> buff.ly/TZ0YRC0
#myeloMATCH
Trial Info -> buff.ly/TZ0YRC0
September 29, 2025 at 11:45 AM
Everybody can reply
#CCTG Trial Highlight for #LeukemiaAwarenessMonth : ALC8 is testing four innovative treatment combinations for newly diagnosed high-risk acute #myeloid #leukemia to find better first-line options for patients.
#myeloMATCH #SolvingCancerTogether
Trial info -> buff.ly/NLWIgT7
#myeloMATCH #SolvingCancerTogether
Trial info -> buff.ly/NLWIgT7
September 22, 2025 at 8:12 PM
Everybody can reply
Analytical performance of the NCI-myeloMATCH assay – a rapid turnaround genomic profiling assay for myeloid disorders. Authors from @fredhutch.bsky.social.
Full text: https://www.jmdjournal.org/article/S1525-1578(25)00116-3/fulltext
Full text: https://www.jmdjournal.org/article/S1525-1578(25)00116-3/fulltext
August 5, 2025 at 1:28 PM
Everybody can reply
1 reposts
3 likes
#myeloMATCH is the NCI’s #PrecisionMedicine trial in #myeloid cancers. Substudy MM1OA-S03
enrolls patients who are age 60+ or unfit for chemo and have newly diagnosed AML with an
IDH2 gene mutation (~15% of pts).
swog.org/clinical-trials/MM1OA-S03 #leusm #leukemia @urochester.bsky.social
enrolls patients who are age 60+ or unfit for chemo and have newly diagnosed AML with an
IDH2 gene mutation (~15% of pts).
swog.org/clinical-trials/MM1OA-S03 #leusm #leukemia @urochester.bsky.social
June 11, 2025 at 7:55 PM
Everybody can reply
NCI approved clinical research studies in metastatic colorectal cancer, pediatric high grade glioma, ALL, head and neck chemo, breast cancer, sub-studies of MyeloMATCH and Lung-MAP, and an education/mentorship study within the NCORP network.
https://cancerletter.com/nci-trials/20250509_12/
https://cancerletter.com/nci-trials/20250509_12/
NCI Trials for May 2025 - The Cancer Letter
The National Cancer Institute approved the following clinical research studies last month. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe
cancerletter.com
May 12, 2025 at 1:00 AM
Everybody can reply
#CCTG has presented the Phase III Program Team Award for an intergroup led trial to the ALC.7 team from Arthur J.E. Child Comprehensive Cancer Centre for their performance on this #myeloMATCH protocol. #CCTG2025
April 27, 2025 at 8:01 PM
Everybody can reply
Very excited to share that that the Myelomatch study I am leading is open to accrual! We are investigating ASTX727 +/- enasidenib in higher-risk IDH2m MDS
clinicaltrials.gov/study/NCT065...
clinicaltrials.gov/study/NCT065...
April 10, 2025 at 8:03 PM
Everybody can reply
1 reposts
2 likes
#myeloMATCH sub-study MM1OA-S03 is open!
Patients registered to MYELOMATCH screening protocol who are 60+ or unfit for chemo and have AML w an IDH2 gene mutation may be assigned. Randomized to venetoclax + ASTX727 w/wo enasidenib.
swog.org/clinical-trials/MM1OA-S03 @beatalleukemia.bsky.social
Patients registered to MYELOMATCH screening protocol who are 60+ or unfit for chemo and have AML w an IDH2 gene mutation may be assigned. Randomized to venetoclax + ASTX727 w/wo enasidenib.
swog.org/clinical-trials/MM1OA-S03 @beatalleukemia.bsky.social
April 2, 2025 at 3:44 PM
Everybody can reply
1 reposts
1 quotes
3 likes
#myeloMATCH substudies treat patients with #AML or #MDS sequentially from diagnosis thru all treatment stages. After each treatment, patients are rescreened for assignment to a substudy in another tier. #NCI @eaonc.bsky.social @swog.org
swog.org/myeloMATCH-overview
swog.org/myeloMATCH-overview
March 31, 2025 at 8:49 PM
Everybody can reply
1 reposts
2 likes
ICYMI: NCI’s myeloMATCH pushes the envelope in myeloid leukemia care
sohoinsider.com/leukemia/nci...
sohoinsider.com/leukemia/nci...
NCI’s myeloMATCH pushes the envelope in myeloid leukemia care
A new National Cancer Institute (NCI) initiative seeks to redefine the standard for personalized cancer care in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Known as myeloMATCH—(M...
sohoinsider.com
March 4, 2025 at 1:48 AM
Everybody can reply
1 likes
The #CCTG ALC8 trial has opened, testing the effects of novel therapeutics for newly diagnosed, untreated acute myeloid leukemia #AML patients. This trial is part of the #myeloMATCH precision medicine protocol for #AML #MDS patients. #SolvingCancerTogether
https://buff.ly/419yN3S
https://buff.ly/419yN3S
February 12, 2025 at 4:07 PM
Everybody can reply
1 reposts
1 likes
myeloMATCH is a large research study for people with #AML and #MDS. Treatment study MM1YA-S01 is for adults younger than 60 with AML. If you haven’t started treatment, ask your doctor about myeloMATCH. swog.org/MM1YA-S01. 1-800-4-CANCER. #leusm #AMLsm #leukemia
January 13, 2025 at 9:03 PM
Everybody can reply
1 likes
#myeloMATCH MM1YA-S01 is enrolling adults ages 18-59 with newly diagnosed high-risk #AML.
Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. swog.org/clinical-tri...
Co-PI: Tara Lin, MD #leusm #AMLsm #leukemia
Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. swog.org/clinical-tri...
Co-PI: Tara Lin, MD #leusm #AMLsm #leukemia
January 8, 2025 at 5:43 PM
Everybody can reply
Dr. Harry Erba interviewed by Society of Hematologic Oncology news on #myeloMATCH trial in AML & MDS: "It’s about creating a model for how we can use science, technology, and collaboration to revolutionize cancer care." @eaonc.bsky.social @dukemedschool.bsky.social
sohoinsider.com/leukemia/nci...
sohoinsider.com/leukemia/nci...
NCI’s myeloMATCH precision medicine initiative pushes the envelope in myeloid leukemia care
A new National Cancer Institute (NCI) initiative seeks to redefine the standard for personalized cancer care in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Known as MyeloMATCH— (M...
sohoinsider.com
January 3, 2025 at 3:15 PM
Everybody can reply
2 likes
MM1YA-S01 is a randomized Tier-1 #myeloMATCH substudy comparing SOC cytarabine + danorubicin induction to 4 other induction therapies in adults <60 yrs w high-risk #AML.
SWOG.org/clinical-trials/MM1YA-S01 #leusm #AMLsm #leukemia
PI: Paul J. Shami, MD @huntsmancancer.bsky.social @mtmdphd.bsky.social
SWOG.org/clinical-trials/MM1YA-S01 #leusm #AMLsm #leukemia
PI: Paul J. Shami, MD @huntsmancancer.bsky.social @mtmdphd.bsky.social
December 17, 2024 at 2:15 PM
Everybody can reply
1 likes
#myeloMATCH is the NCI’s #precisionmedicine trial in #myeloid cancer: advanced biomarker testing in newly diagnosed acute myeloid #leukemia (#AML) or #myelodysplastic syndrome (#MDS) & treatment substudies by the Alliance, Canadian Cancer Trials Group, @eaonc.bsky.social & SWOG. swog.org/myeloMATCH
December 6, 2024 at 7:58 PM
Everybody can reply
4 reposts
1 quotes
10 likes
#APTO Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
#news #investing #stocks
https://www.stocktitan.net/news/APTO/aptose-signs-crada-with-nci-to-develop-tuspetinib-for-aml-and-mds-in-tj1xgx9x1rpp.html
#news #investing #stocks
https://www.stocktitan.net/news/APTO/aptose-signs-crada-with-nci-to-develop-tuspetinib-for-aml-and-mds-in-tj1xgx9x1rpp.html
Aptose Partners with NCI to Advance Tuspetinib Cancer Treatment in Clinical Trials | APTO Stock News
Aptose Biosciences teams with National Cancer Institute to develop tuspetinib for AML/MDS treatment through myeloMATCH trials, plus launches Phase 1/2 TUSCANY study.
www.stocktitan.net
December 3, 2024 at 12:30 PM
Everybody can reply
1 likes